CSCIFOTCPerfumes, Cosmetics & Other Toilet PreparationsFiscal year ends December 31
COSCIENS Biopharma Inc.
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 20-F on Mar 25, 2026
$6.49+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $24.10M
- P/E (TTM)
- –
- Dividend yield
- –
COSCIENS Biopharma Inc. revenue by segment
By business segment
| Revenue | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | Q2 23 | Q1 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Active ingredient [member] | $1.76M | $1.48M | $2.42M | $1.39M | $2.39M | $1.71M | $2.33M | $2.06M | $1.21M | $1.95M | $1.39M | – | 99.5% | -26.6% |
| Biopharmaceutical [member] | – | – | – | – | $928.00K | $164.00K | $3.00K | – | – | – | – | – | – | – |
| Pharmaceutical [member] | – | $7.00K | $332.00K | $113.00K | $928.00K | $164.00K | $3.00K | – | – | – | – | – | – | – |
By product or service
| Revenue | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | Q2 23 | Q1 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License fees [member] | – | – | – | – | – | – | – | – | – | $0 | $795.00K | $760.00K | – | – |
| Royalties [member] | – | – | – | – | – | – | – | – | – | $3.00K | $7.00K | $18.00K | – | – |
| Supply chain [member] | – | – | – | – | – | – | – | – | – | $0 | $42.00K | $11.00K | – | – |
| Development services [member] | – | – | – | – | – | – | – | – | – | $0 | $1.40M | $1.34M | – | – |
By region
From the segment and revenue-disaggregation notes of COSCIENS Biopharma's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.